GIHCG and cancer: Knocking-down of GIHCG could significantly enhance the sensitivity to Lapatinib in MCF7 and BxPC3 cancer cell lines (Figure 7D), while down-regulation of SPINT1-AS1 could promote resistance to Lapatinib in NCI-N87 and MCF7 cancer cell lines (Figure 7E).